GlassScriptPhysician profile
Amanda J Yatabe
NPI 1316537756
$2,703.52
in general payments reported to CMS, 2019-2025
26 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $627 · 2022: $567 · 2023: $425 · 2024: $713 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502 · Education: $6.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.48 |
| Education | $6.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $419.79 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $410.25 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $409.23 | 2022-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $333.66 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Novo Nordisk INC | $278.15 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $111.26 | 2022-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $96.12 | 2024-2025 | Cobenfy |
| Amgen INC. | $68.12 | 2021-2023 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $65.45 | 2021-2022 | |
| Lilly USA, LLC | $52.10 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.09 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $45.94 | 2021 | |
| Dexcom, INC. | $40.39 | 2021-2023 | Dexcom G6 Transmitter |
| Indivior INC. | $38.42 | 2024 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.42 | 2022-2024 | Caplyta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $30.36 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $29.40 | 2021-2022 | |
| Glaxosmithkline, LLC. | $29.12 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $28.74 | 2025 | Hetlioz, Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.98 | 2022 | |
| Antares Pharma, INC. | $20.47 | 2022 | |
| Pfizer INC. | $19.78 | 2022 | |
| Alkermes, INC. | $19.00 | 2023 | Aristada, Lybalvi |
| Sanofi-Aventis U.S. LLC | $15.58 | 2022 | |
| Luye Pharma (USA) LTD. | $15.01 | 2025 | Erzofri Extended-Release |
| Vistapharm, INC. | $14.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Yatabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.